Curevac announces closing of $250 million follow-on public offering of common shares

TÜbingen, germany and boston, ma / accesswire / february 10, 2023 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), announced today the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by curevac.
CVAC Ratings Summary
CVAC Quant Ranking